Infiniti

All surgeries were performed using Infiniti (Alcon laboratories, Inc., Fort Worth, TX, USA) under topical anaesthesia by one surgeon (TŻ) through 2.2 mm incision in the upper corneal limbus. The implantation of Aspira-aA (HumanOptics AG, Erlangen, Germany) intraocular lens to the capsular bag was performed in all cases.

Cataract surgery was performed in all patients through a clear corneal incision under topical anesthesia using an Infiniti^® phacoemulsification unit (Alcon, Fort Worth, TX, USA). Intraoperative complications were recorded in all patients. Patients were postoperatively evaluated at seven and 30 days. Patients with a normal postoperative clinical course moved to community-based ophthalmology clinics for follow-up. Those with complications or unsatisfactory post-surgical results remained in the department for follow-up. Data up to one month of follow-up was collected from patients who remained under observation in the department. Only senior surgeons and young consultants (>4 years of surgery experience with over 150 cases) had operated on the older subjects group, as our department’s protocol considers an age over 88 years to be a significant risk factor [18 (link)].

After instillation of topical anesthesia (0.5% proparacaine hydrochloride), the phacoemulsification surgery was performed. A continuous curvilinear capsulorrhexis marker with a 6.0-mm diameter was used to reference the corneal plane. The main clear corneal incision was made using a 2.2-mm keratome, followed by capsulorrhexis using a capsulorrhexis needle. Phacoemulsification was performed using either the Infiniti® or Centurion® phacoemulsifier (Alcon Laboratories, Inc., Fort Worth, TX, USA). Using an injector, a + 2.75 D multifocal IOL was implanted into the capsular bag of the dominant eye, and a + 4.00 D multifocal IOL was implanted into the capsular bag of the nondominant eye. The dominant eye was first implanted with Tecnis + 2.75 D multifocal IOL (ZKB00), and 1 week after surgery in the dominant eye, Tecnis + 4.00 D multifocal IOL (ZMB00) was implanted in the non-dominant eye. The target postoperative refraction was emmetropia in both eyes. All patients were administered 0.5% gatifloxacin ophthalmic solution (Gatiflo®, HANDOK, Seoul, South Korea) and prednisolone eye drops (Pred-Forte®, Allergan, Dublin, Ireland) for 1-month postoperatively. All of the above surgical protocols were equally applied to the bilaterally monofocal IOLs implanted group.

A retrospective study on 37 patients, who underwent phacoemulsification (37 eyes) surgery during the period 2009–2014 for complicated cataract after endogen anterior uveitis, was performed. 21 patients were males (56,75%), 16 females (43,25%). Patients’ age and sex distribution is represented in Fig. 1. Three patients presented ankylosing spondylitis, one patient presented psoriasis with arthritis, and the others idiopathic anterior uveitis. Phacoemulsification surgery was performed with 2,2 mm incision with Alcon Infiniti and Alcon Constellation systems. All the patients underwent surgery only if they presented a minimum period of 6 months of inactive inflammation.

All surgeries were performed using Infiniti (Alcon laboratories, Inc., Fort Worth, TX, USA) under topical anaesthesia by one surgeon (TŻ) through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of Aspira-aA (HumanOptics AG, Erlangen, Germany) to the capsular bag was performed in all cases.